NM_020975.6(RET):c.82G>A (p.Gly28Ser) AND Multiple endocrine neoplasia, type 2

Germline classification:: Uncertain significance (2 submissions)
Last evaluated:: Dec 1, 2023
Review status:: 2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV000807337.10

Allele description [Variation Report for NM_020975.6(RET):c.82G>A (p.Gly28Ser)]

NM_020975.6(RET):c.82G>A (p.Gly28Ser)

Gene:

RET:ret proto-oncogene [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

10q11.21

Genomic location:

Preferred name:

NM_020975.6(RET):c.82G>A (p.Gly28Ser)

Other names:

p.Gly28Ser

HGVS:

NC_000010.11:g.43100467G>A
NG_007489.1:g.28399G>A
NM_000323.2:c.82G>A
NM_001406743.1:c.82G>A
NM_001406744.1:c.82G>A
NM_001406759.1:c.82G>A
NM_001406760.1:c.82G>A
NM_001406761.1:c.82G>A
NM_001406762.1:c.82G>A
NM_001406763.1:c.82G>A
NM_001406764.1:c.82G>A
NM_001406765.1:c.82G>A
NM_001406766.1:c.82G>A
NM_001406767.1:c.82G>A
NM_001406768.1:c.82G>A
NM_001406769.1:c.82G>A
NM_001406770.1:c.82G>A
NM_001406771.1:c.82G>A
NM_001406772.1:c.82G>A
NM_001406773.1:c.82G>A
NM_001406774.1:c.82G>A
NM_001406775.1:c.82G>A
NM_001406776.1:c.82G>A
NM_001406777.1:c.82G>A
NM_001406778.1:c.82G>A
NM_001406779.1:c.82G>A
NM_001406780.1:c.82G>A
NM_001406781.1:c.82G>A
NM_001406782.1:c.82G>A
NM_001406783.1:c.82G>A
NM_001406785.1:c.82G>A
NM_001406786.1:c.82G>A
NM_001406787.1:c.82G>A
NM_001406788.1:c.82G>A
NM_001406789.1:c.82G>A
NM_001406790.1:c.82G>A
NM_001406791.1:c.82G>A
NM_020629.2:c.82G>A
NM_020630.7:c.82G>A
NM_020975.6:c.82G>AMANE SELECT
NP_000314.1:p.Gly28Ser
NP_001393672.1:p.Gly28Ser
NP_001393673.1:p.Gly28Ser
NP_001393688.1:p.Gly28Ser
NP_001393689.1:p.Gly28Ser
NP_001393690.1:p.Gly28Ser
NP_001393691.1:p.Gly28Ser
NP_001393692.1:p.Gly28Ser
NP_001393693.1:p.Gly28Ser
NP_001393694.1:p.Gly28Ser
NP_001393695.1:p.Gly28Ser
NP_001393696.1:p.Gly28Ser
NP_001393697.1:p.Gly28Ser
NP_001393698.1:p.Gly28Ser
NP_001393699.1:p.Gly28Ser
NP_001393700.1:p.Gly28Ser
NP_001393701.1:p.Gly28Ser
NP_001393702.1:p.Gly28Ser
NP_001393703.1:p.Gly28Ser
NP_001393704.1:p.Gly28Ser
NP_001393705.1:p.Gly28Ser
NP_001393706.1:p.Gly28Ser
NP_001393707.1:p.Gly28Ser
NP_001393708.1:p.Gly28Ser
NP_001393709.1:p.Gly28Ser
NP_001393710.1:p.Gly28Ser
NP_001393711.1:p.Gly28Ser
NP_001393712.1:p.Gly28Ser
NP_001393714.1:p.Gly28Ser
NP_001393715.1:p.Gly28Ser
NP_001393716.1:p.Gly28Ser
NP_001393717.1:p.Gly28Ser
NP_001393718.1:p.Gly28Ser
NP_001393719.1:p.Gly28Ser
NP_001393720.1:p.Gly28Ser
NP_065680.1:p.Gly28Ser
NP_065681.1:p.Gly28Ser
NP_065681.1:p.Gly28Ser
NP_065681.1:p.Gly28Ser
NP_066124.1:p.Gly28Ser
NP_066124.1:p.Gly28Ser
LRG_518t1:c.82G>A
LRG_518t2:c.82G>A
LRG_518:g.28399G>A
LRG_518p1:p.Gly28Ser
LRG_518p2:p.Gly28Ser
NC_000010.10:g.43595915G>A
NM_020630.4:c.82G>A
NM_020630.6:c.82G>A
NM_020975.4:c.82G>A

Protein change:

G28S

Links:

dbSNP: rs779905135

NCBI 1000 Genomes Browser:

rs779905135

Molecular consequence:

NM_000323.2:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406743.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406744.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406759.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406760.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406761.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406762.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406763.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406764.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406765.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406766.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406767.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406768.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406769.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406770.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406771.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406772.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406773.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406774.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406775.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406776.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406777.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406778.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406779.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406780.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406781.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406782.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406783.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406785.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406786.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406787.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406788.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406789.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406790.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001406791.1:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_020629.2:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_020630.7:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_020975.6:c.82G>A - missense variant - [Sequence Ontology: SO:0001583]

Observations:

Condition(s)

Name:: Multiple endocrine neoplasia, type 2 (MEN2)
Identifiers:: MONDO: MONDO:0019003; MedGen: C4048306

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV000947385	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Nov 17, 2023)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]
SCV004838623	All of Us Research Program, National Institutes of Health	criteria provided, single submitter (ACMG Guidelines, 2015)	Uncertain Significance (Dec 1, 2023)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV000947385

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Nov 17, 2023)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

SCV004838623

All of Us Research Program, National Institutes of Health

criteria provided, single submitter

(ACMG Guidelines, 2015)

Uncertain Significance
(Dec 1, 2023)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	6	not provided	not provided	108544	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group, Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee.

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]

PMID:: 25741868
PMCID:: PMC4544753

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000947385.6

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 28 of the RET protein (p.Gly28Ser). This variant is present in population databases (rs779905135, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with RET-related conditions. ClinVar contains an entry for this variant (Variation ID: 651895). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

From All of Us Research Program, National Institutes of Health, SCV004838623.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	6	not provided	not provided	clinical testing	PubMed (1)

Description

This missense variant replaces glycine with serine at codon 28 of the RET protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with RET-related disorders in the literature. This variant has been identified in 4/278834 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	108544	not provided	not provided		6	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine